Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells
暂无分享,去创建一个
S. Canevari | R. Kontermann | A. Desideri | F. Iacovelli | A. Anichini | M. Di Nicola | D. Mezzanzanica | A. Gianni | M. Figini | F. Caroli | B. Frigerio | A. Satta
[1] H. Walczak,et al. Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy , 2017, Nature Reviews Cancer.
[2] Ulrich Brinkmann,et al. The making of bispecific antibodies , 2017, mAbs.
[3] G C P van Zundert,et al. The HADDOCK2.2 Web Server: User-Friendly Integrative Modeling of Biomolecular Complexes. , 2016, Journal of molecular biology.
[4] Berk Hess,et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers , 2015 .
[5] L. Buie,et al. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia. , 2015, The Annals of pharmacotherapy.
[6] G. Sethi,et al. Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy , 2015, Experimental biology and medicine.
[7] M. Sanford. Blinatumomab: First Global Approval , 2015, Drugs.
[8] U. Brinkmann,et al. Bispecific antibodies. , 2015, Drug discovery today.
[9] B. Aggarwal,et al. Targeting death receptors for TRAIL by agents designed by Mother Nature. , 2014, Trends in pharmacological sciences.
[10] S. Canevari,et al. Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma , 2014, Cell Death and Disease.
[11] A. Rosato,et al. A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer. , 2013, European journal of cancer.
[12] S. Canevari,et al. Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors. , 2013, Future oncology.
[13] Diana Gil,et al. Strategies to stabilize compact folding and minimize aggregation of antibody-based fragments , 2013, Advances in bioscience and biotechnology.
[14] P. Kufer,et al. Blinatumomab: a historical perspective. , 2012, Pharmacology & therapeutics.
[15] M. Manns,et al. Epitope spreading of the anti-CYP2D6 antibody response in patients with autoimmune hepatitis and in the CYP2D6 mouse model. , 2011, Journal of autoimmunity.
[16] L. Diaz,et al. Systemic use of tumor necrosis factor alpha as an anticancer agent , 2011, Oncotarget.
[17] Hermann Einsele,et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] P. Baeuerle,et al. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. , 2011, Experimental cell research.
[19] P. Moore,et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. , 2011, Blood.
[20] F. Stricher,et al. Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants , 2010, Cell Death and Disease.
[21] Robert Mabry,et al. Therapeutic bispecific antibodies: The selection of stable single-chain fragments to overcome engineering obstacles. , 2010, IDrugs : the investigational drugs journal.
[22] P. Moore,et al. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. , 2010, Journal of molecular biology.
[23] R. Kontermann. Alternative antibody formats. , 2010, Current opinion in molecular therapeutics.
[24] C. la Vecchia,et al. Elevated levels of the acute‐phase serum amyloid are associated with heightened lung cancer risk , 2010, Cancer.
[25] W. Quax,et al. Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors. , 2009, Biochemistry.
[26] A. Lugovskoy,et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR , 2009 .
[27] Scott M Glaser,et al. Antibody therapeutics, antibody engineering, and the merits of protein stability. , 2008, Current opinion in drug discovery & development.
[28] Paolo Marcatili,et al. PIGS: automatic prediction of antibody structures , 2008, Bioinform..
[29] H. Einsele,et al. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.
[30] A. Ashkenazi,et al. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] D. Lawrence,et al. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5 , 2008, Cell Death and Differentiation.
[32] Holger Gohlke,et al. The Amber biomolecular simulation programs , 2005, J. Comput. Chem..
[33] P. Kufer,et al. BiTEs: bispecific antibody constructs with unique anti-tumor activity. , 2005, Drug discovery today.
[34] G. Screaton,et al. Expression of TRAIL and TRAIL receptors in normal and malignant tissues , 2005, Cell Research.
[35] Conrad C. Huang,et al. UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..
[36] K. Knutson,et al. Humoral Epitope-Spreading Following Immunization with a HER-2/neu Peptide Based Vaccine in Cancer Patients , 2004, Journal of Clinical Immunology.
[37] A. Ashkenazi,et al. Apo2L/TRAIL and its death and decoy receptors , 2003, Cell Death and Differentiation.
[38] A. Ashkenazi,et al. Targeting death and decoy receptors of the tumour-necrosis factor superfamily , 2002, Nature Reviews Cancer.
[39] C. J. Hutchings,et al. Generation of Naive Human Antibody Libraries , 2001 .
[40] C. Rauch,et al. Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.
[41] S. Canevari,et al. Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection. , 1998, Cancer research.
[42] S. Marsters,et al. Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family* , 1996, The Journal of Biological Chemistry.
[43] C A Smith,et al. Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.
[44] S. Nagata,et al. Lethal effect of the anti-Fas antibody in mice , 1993, Nature.
[45] T. Darden,et al. Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .
[46] H R Hoogenboom,et al. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. , 1991, Journal of molecular biology.
[47] A. Lanzavecchia,et al. The use of hybrid hybridomas to target human cytotoxic T lymphocytes , 1987, European journal of immunology.
[48] P. Capel,et al. Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells , 1983, Nature.
[49] G. Ciccotti,et al. Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .